CA-CLICKHOUSE
30.7.2024 16:01:35 CEST | Business Wire | Press release
ClickHouse, Inc., the company behind the world’s fastest and most popular real-time analytical database, is thrilled to announce the acquisition of PeerDB, a leading provider of change data capture (CDC) solutions for Postgres databases. This strategic acquisition underscores ClickHouse’s commitment to delivering unparalleled real-time analytics and data integration capabilities to its customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240730221289/en/
ClickHouse acquires PeerDB to boost real-time analytics with Postgres CDC integration (Graphic: Business Wire)
PeerDB’s technology significantly reduces the time it takes to connect data in transactional databases like Postgres with analytical databases like ClickHouse, boosting developer productivity and time-to-value when building real-time data driven applications. With PeerDB CDC technology integrated into ClickHouse Cloud, users will benefit from seamless, real-time data replication from Postgres databases to ClickHouse.
“We are excited to welcome PeerDB into ClickHouse,” said Aaron Katz, CEO of ClickHouse, Inc. “This acquisition aligns with our mission to empower our customers with the most advanced and efficient data analytics solutions. By integrating PeerDB’s CDC technology, we are empowering Postgres developers to move even faster when building real-time data driven applications. Now, all they have to do is configure a mirror between their existing Postgres databases and ClickHouse, and the data is available for lightning-fast analytical queries.”
Sai Krishna Srirampur, CEO of PeerDB, expressed his enthusiasm for what the future holds, stating, “We are thrilled to join forces with ClickHouse. This acquisition is a natural evolution for us at PeerDB, as we already share many joint enthusiastic users with ClickHouse. Postgres is becoming the de facto operational database, while ClickHouse is the fastest analytical database on the planet. Both originate from the same open-source ethos. This acquisition bridges the gap between Postgres and ClickHouse, enabling businesses to seamlessly move their operational data for real-time analytics.”
Javier Erro Garcia, Cloud Architecture Manager at Vueling Airlines, shared excitement about the upcoming integration: “As a user of both ClickHouse Cloud and PeerDB, I am thrilled about this acquisition. We already reduced our Postgres to ClickHouse snapshot times from 10+ hours down to 15 minutes with PeerDB. Combining ClickHouse’s powerful analytics natively with PeerDB’s real-time data capture capabilities will greatly simplify our data processing workflows. This integration will enable us to build analytical applications faster, giving us a competitive edge in the market.”
The combined expertise of ClickHouse and PeerDB will pave the way for the development of new features and capabilities aimed at meeting the evolving needs of data-driven enterprises. Customers can look forward to deeper integration between PeerDB Cloud and ClickHouse Cloud and support for additional CDC data sources. The ClickHouse technical blog post introducing the acquisition provides more detail.
About ClickHouse
ClickHouse is a fast, open-source, columnar OLAP database management system. It allows users to generate analytics using SQL queries in real-time. Designed to analyze large volumes of data, ClickHouse is used by industry leaders around the globe for its unmatched performance, scalability, and reliability.
About PeerDB
PeerDB is a leading provider of change data capture (CDC) solutions for Postgres databases. Their technology enables real-time data replication and synchronization, helping businesses keep their data up-to-date and accessible for analytics and decision-making processes.
PeerDB was founded by Kaushik Iska and Sai Srirampur in mid 2023 and has since grown to become a leading Postgres data replication company in the market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730221289/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom